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Abstract
Background: Gastrointestinal stromal tumors (GIST) are mesenchymal tumors of the gastrointestinal tract, usually
kit-positive, that are believed to originate from interstitial cell of Cajal, or their related stem cells. The most
common clinical presentation of these tumors is gastrointestinal bleeding, otherwise they may cause intestinal
obstruction, abdominal pain, a palpable mass, or can be incidentally detected during surgery or endoscopic/
radiological procedures. Prognosis is related to the size of the tumor and to the mitotic rate; other prognostic
factors are tumor location, tumor resection margins, tumor rupture, and c-kit mutation that may interfere with
molecular target therapy efficacy.
Aim: Primary aim of this study was to report our experience regarding GIST patients, correlating symptoms at
presentation with tumor localization and risk factors.
Patients and methods: 47 consecutive patients undergone to surgical resection for GISTs were enrolled in a
prospective study from December 1999 to March 2009. Patient’s clinical and pathological features were collected
and analysed.
Results: The most common symptom was abdominal pain. Bleeding in the digestive tract and abdominal pain
were more frequent in gastric GISTs (58% and 61%); acute abdominal symptoms were more frequent in jejunal and
ileal GISTs (40% and 60%), p < 0.05. We reported a mild correlation between the mitotic rate index and symptoms
at presentation (p 0.074): this correlation was stronger if GISTs causing “acute abdominal symptoms” were
compared with GISTs causing “abdominal pain” as main symptom (p 0.039) and with “incidental” GISTs (p 0.022).
We observed an higher prevalence of symptomatic patients in the “high risk/malignant group” of both the
Fletcher’s and Miettines’s classification (p < 0.05).
Conclusion: According with our findings symptoms correlate to tumor location, to class risk criteria as mitotic
index and risk classifications, however we cannot conclude that symptoms are per se predictive of survival or
patient’s outcome.
Background
Gastrointestinal stromal tumors (GIST) are mesenchy-
mal tumors of the gastrointestinal (GI) tract, usually kit-
positive, that are believed to originate from interstitial
cell of Cajal (ICC), the gut pacemaker of the autonomic
nervous gut system, or their related stem cells [1,2].
GISTs usually occur in adults, with a median age of
55-60 years and incidence of 10 to 20 new cases per
million/year [3]. GISTs represent 80% of mesenchymal
gastrointestinal tumors and 0.1-3% of all gastrointestinal
malignancies [4-7]. GIST’s pathogenesis is related to kit
and platelet-derived growth factor receptor alpha
(PDGFR alpha) mutation. kit and PDGFR alpha encode
for similar type III receptor tyrosine kinase proteins:
these mutations are somatic and occur only in the
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tional mutations in familial GISTs occur in every cells
of the body and are inheritable [8-11].
GISTs have specific immunohistochemical (IHC) mar-
kers: 95% are CD-117 positive, 70-80% are CD34 posi-
tive, and 20-30% are smooth muscle actin (SMA)
positive, whereas desmin is positive in less than 5% of
GISTs [1,12]. Discovered on GIST (DOG) 1, known also
as ANO1, has emerged in recent years as a promising
biomarker for GISTs, since recent studies documented
that DOG1 antibodies are more sensitive than kit anti-
bodies in detecting gastric GISTs and tumors carrying
PDGFR alpha mutations [13].
GISTs may develop through all the GI tract: 50-70%
in the stomach, 25-30% in the small intestine, 5-10% in
the colon-rectum, < 5% in the esophagus, the remaining
may arise within the omentum or within the peritonel
layers (Extra-Gastro-intestinal Stromal Tumors, EGISTs)
[12,14,15]. Familial GISTs are very rare, occurring in
patients with inheritable germline kit or PDGFR alpha
mutations; 5% of GISTs occur in patients with Neurofi-
bromatosis type 1 syndrome and in Carnery triad (gas-
tric GIST, paraganglioma, pulmonary chondroma) [1].
The most common clinical presentation of these
tumors is GI bleeding (with acute hematemesis, mel-
aena, or chronic anemia); they may cause GI obstruc-
tion, abdominal pain, weight loss or a palpable mass,
otherwise they can be incidentally detected during sur-
gery or endoscopic/radiological procedures [6,16-18].
Prognosis is related to the size of the tumor and to
the mitotic rate: tumors > 10 cm or with a mitotic rate
of >5 per 50 HPF have a higher risk of recurrence and
metastatic spread and are associated with a poor prog-
nosis (approximately 20-30% of GISTs). Other prognos-
tic factors are tumor location, the persistence of tumor
residuals within the surgical resection margins, tumor
rupture, and c-kit mutation that may interfere with
molecular target therapy efficacy [19-22].
State of the art in GIST’s treatment is based on two
gold standards: surgery and target molecular therapy.
The aim of surgical treatment is complete resection,
avoiding tumor rupture, preferring wedge resections
whenever possible; lymphadenectomy is not recom-
mended due to the rarity of nodal metastasis, with the
exception of GISTs occurring in a setting of Carney
triad, that usually show an higher rate of lymph node
metastasis [23].
The majority of kit-mutant proteins are sensitive to
agents that block KIT and PDGFR alpha, like Imatinib,
with a response rate that reaches almost 70% even in
advance disease [24], however resistance to the therapy
has been widely reported [25].
T h ea i mo ft h ep r e s e n ts t u d yw a st or e p o r to u r
experience on 47 consecutive patients undergone to
surgical resection for GIST tumors, correlating symp-
toms at presentation with a) tumor’s localization, and b)
risk factors and classification.
Patients and Methods
Study protocol and patients
Fifty-one consecutive patients referred for surgical treat-
ment for GIST tumors were enrolled in a prospective-
observational study: thirteen patients (from December
1999 to March 2003) at the Department of Surgery “Pie-
tro Valdoni” of University of Rome “La Sapienza”,a n d
thirty-eight patients (from April 2003 to March 2009),
were recorded, by the same surgical team, at Sant’Andrea
Hospital of Rome, Faculty of Medicine and Psychology,
University of Rome “La Sapienza”.
Within this group, only patients presenting with a pri-
mary GIST tumors, surgically resectable, were selected.
Patients presenting with metastatic disease, were first
referred to the Oncology Unit before surgical treatment,
and then selected if surgical resection was indicated as
primary treatment. Three patients not suitable for surgi-
cal treatment due to co-morbidity, and due to spreading
of the disease were excluded; one patient was excluded
because presenting with a recurrence of a GIST pre-
viously treated else-where.
According with these criteria, forty-seven patients out
of fifty-one observed, were enrolled in an observational
study. Authorization of the ethical board was not
required for this study, but signed consent for treatment
and evaluation of the data was obtained from all
selected patients.
Patients were staged through chest and abdominal
computer tomography (CT) scan; magnetic resonance
(MR), was employed as a second-line imaging assess-
ment, at radiologist’s discretion. Endoscopic ultrasound
scan (EUS) was employed to support diagnosis and define
mucosal infiltration of four gastric GISTs. Rectal GISTs
were staged through trans-anal ultrasound and MR.
The aim of surgical treatment was a complete surgical
resection with negative resection margins (R0), sparing
the organ whenever possible, without lymphadenectomy.
Laparoscopic resection was performed whenever possi-
ble, according with tumor size (2-5 cm) and tumor
localization.
R1 (persistence of microscopic tumor deposits within
the resection margins) and R2 (persistence of macro-
scopic tumor residual) resections, or relapse of disease
after R0 resection, presence of high risk factors criteria
or metastases at the time of surgical procedure were
considered as indications for adjuvant therapy. Histolo-
gical processing was obtained with formalin fixation fol-
lowed by paraffin inclusion, 3 μm sectioning, and
staining with hematoxylin and eosin. Morphologic
appearance and cellular descriptions referred to standard
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Mitotic Index (MI) was obtained counting mitotic fea-
tures in 50 consecutive microscopic high-powered fields
(HPF), 400×. IHC processing was carried through anti-
bodies for CD117 (c-kit), S-100 protein and CD-34 and
SMA-alpha. Patients showing recurrence/persistence of
the disease at follow-up were investigated for c-kit
mutation profile.
All patients were clinically evaluated each 3 months
for the first year, each 6 months later after. Follow-up
imaging evaluation was carried through PET scan,
abdominal ultrasound, CT or MR scan according with
the RECIST and Choi’s criteria for response assessment
[26].
Classification
GISTs were classified according to risk prognostic clas-
sifications of Fletcher (NIH 2002) and Miettinen (AFIP
2006, NCCN 2007) [27,28].
Data collection and statistical analysis
Symptoms were recorded on the admission and col-
lected by the team. Data regarding symptoms at presen-
tation, tumor localization, and risk factors of all selected
patients were collected in a database (Visual Fox Pro
7.0, Microsoft Corporation
®), up-dating follow-up each
3-6 months regarding symptoms, adjuvant therapy,
relapse of the disease; statistical analysis was carried
through the SPSS software (SPSS for Window 9.0
®),
using the t-Student’st e s t ,c
2’st e s to rF i s h e r ’s test, and
Kruskal-Wallis’s test; p < 0.05 was considered as statisti-
cal significance value; Kaplan-Meier survival curves and
Logrank test for comparison of survival curves were
obtained through the MedCalc software version 11.4.4.0.
Results
Forty-seven consecutive patients were selected, twenty-
nine males and eighteen females (M/F = 1,61), mean
age 61.4 years (range: 27-84 years, median 62, DS =
+-15.61); no difference of age at diagnosis was recorded
between the two sex.
Table 1 summarize tumor’s localization. Twenty-eight
patients had gastric GIST, three duodenal, six jejunal,
five had a GIST localized within the small bowel, three
rectal (one localized at the anal canal level), one had an
esophageal GIST, the remaining one was considered as
an EGIST, since it was localized within the mesocolon
root. One patient with jejunal GIST had Neurofibroma-
tosis type I. Seven patients (15%) had metastases at the
time of diagnosis (three liver, four peritoneal; Figure 1).
All selected patients underwent to surgical resection:
85% elective, 15% in emergency. R0 resection was
achieved in all patients, with the exclusion of one bulky
GIST of the rectum, who had an R1 low anterior
resection, but was successively R0 after a Miles abom-
ino-perineal amputation. Total laparoscopic resection
was achieved in seven patients, all with gastric GISTs,
with a diameter range between 2 and 4.5 cm. Two
patients with gastric GISTs were converted to open sur-
gery due to the tumor’s localization causing a poor
visualization of anatomy and thus difficult resections.
Histology was consistent with spindle-shaped cells in
48.6%, epithelioid in 32.5%, mixed in 18.9% of the cases.
Gastric GISTs showed a mild prevalence of spindle-shaped
cells if compared to epithelioid and mixed pattern (50% vs
32% and 18%, p 0.056). All GISTs expressed CD117 ran-
ging from 60% to 100%; CD34 was positive in 81%.
Eighteen patients were actin positive and fifteen patients
were S100 positive. IHC positivity to CD117, CD34 and
S100 was not related to GIST location (p 0.096).
No peri-operative mortality was recorded; mean hospi-
talization was 6.9 days (range: 3-15 days). Post-operative
course after laparoscopy was mildly shorter if compared
with standard open surgical resections (mean 5.2 days
vs 6.9 days).
Symptoms at presentation
Table 2 summarizes the clinical presentations and
tumor locations. The most common symptom was
abdominal pain, mainly epigastric or periumbilical
(18 patients).
Five patients had acute abdominal symptoms; associ-
ate symptoms were: vomiting, asthenia, dyspepsia, fever,
weight loss and dysphagia. A palpable abdominal mass
was detected in five patients (10.6%). Nine patients
showed no signs or symptoms, had an incidental diag-
nosis and were considered asymptomatic (19.1%).
Forty patients (85%) underwent to elective resection,
otherwise seven patients (15%) underwent to emergency
resection: three due to bowel obstruction, three due to
bleeding, one patient due to a suspected appendicitis.
Four patients (1 jejunal, 2 gastric, 1 ileal) had an inci-
dental diagnosis of GIST at laparotomy for other rea-
sons (three colon cancers and one hepatic abscess).
Table 1 GIST locations and frequencies in our population
study group
Localization Patients (n) (%)
Gastric 28 59,6
Duodenal 3 6,4
Jejunal 6 12,8
Small bowel 5 10,6
Rectal 3 6,4
Esophageal 1 2,1
Mesocolon root (EGIST) 1 2,1
Tot 47 100%
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sis of GIST, due to a suspected gastritis, epigastralgia or
to progressive weight loss.
Fourteen patients (29,8%) reported acute anemia
(mean Hb 7.6 g/dl), due to high digestive bleeding in
twelve patients, rectorrhagia in one patient, and enteror-
rhagia with hemoperitoneum in the remaining one; four
patients reported a chronic sideropenic anemia.
Tumor location
Bleeding was mainly reported in gastric GISTs, however
this was due to the higher rate of gastric GIST in our
population (Table 2). On the basis of this background,
patients reporting mucosal ulceration and bleeding, were
stratified according with tumor’s localization: results of
this analysis documented that these symptoms were seen
more frequently in duodenal GISTs (2 out of 3 patients,
66%), rectal GISTs (1 out of 3 patients, 33%), comparing
with gastric GISTs (8 out of 28 patients, 28%) and jejunal
GISTs (1 out of 6 patients, 16%) (Figure 2).
Statistical analysis showed that bleeding in the digestive
tract and abdominal pain were more frequent in gastric
GISTs comparing with other localizations (58% and 61%)
otherwise acute abdominal symptoms were more fre-
quent in jejunal and ileal GISTs (40% and 60%), p < 0.05.
Indeed in our experience, five out of seven patients
undergone to an emergency surgical resection (three
due to a bowel obstruction and two due to GI bleeding),
had jejunal/ileal GISTs.
Risk factors and classification
Mean maximum tumor diameter (MMTD) was 7,4 cm
(median 5.0, DS +- 6,72, range 1-33 cm). Tumor size
was not related to age, sex or location (gastric vs other
locations p 0.808).
Gastric GISTs showing abdominal pain were larger in
size than those showing bleeding as main symptom, but
statistical analysis failed in detecting a significant differ-
ence within these groups (p 0.077); similar jejunal/ileal
GISTs showing acute abdominal symptoms were larger
in size (with a mean diameter of 13.2 cm) comparing
with jejunal/ileal GISTs showing other symptoms at pre-
sentation, the difference, however did not reach a signif-
icant value (p n.s.).
Figure 1 Metastases from primary GIST tumors. a) CT scan of liver mestastases from GIST tumor. b) Peritoneal metastases from primary GIST
tumor.
Table 2 Clinical presentation, symptoms and GIST localization reported in our population study group
Clinical presentation and Symptoms
GIST localization GI bleeding Abdominal pain Acute abdomen Palpable mass Asymptomatic
Gastric 8 11 - 2 6
Duodenal 2 1 - - -
Jejunal 1 1 2 1 2
Small bowel 2 1 3 1 1
Rectal 1 2 - - -
Esophageal - 1 - - -
EGIST - 1 - 1 -
(NB. each GIST might have more then one symptom reported, eg 1 EGIST padient: abdominal pain plus papable mass, thus total ≠ 47).
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wise four patients (8.5%) ranged between 5 and 10/50
HPF and eight patients (17%) had a MI > 10/50 HPF.
Results of our analysis showed a correlation between
MI and tumor’s location, since there was a significant
difference if gastric GISTs were compared with duode-
nal GISTs (p 0.018).
We reported a mild correlation between MI and symp-
toms at presentation (Kruskal-Wallis test H = 7.532, 3 gl,
p 0.074); this correlation was stronger if GISTs causing
“acute abdominal symptoms” were compared with GISTs
causing “abdominal pain” as main symptom (p 0.039)
and with “incidental” GISTs (p 0.022).
Patients were stratified according with Fletcher’sa n d
Miettinen’s risk factor criteria: Table 3 shows differences
within these two classifications and the consequent re-
distribution of patients in our population study group
regarding tumor localization and risk factors groups.
Figure 2 Surgical specimen of a jejunal GIST: the blood clot placed on the right side revealed the tumor causing the mucosal
ulceration.
Table 3 Fletchers’s and Miettinen’s Classification of GIST tumors: distribution of symptoms, tumor locations, tumor’s
diameter and surgical procedures in our population study group
Fletcher’s Classification (NIH 2002) Miettinen’s Classification (AFIP 2006, NCCN 2007)
Very Low Low Intermediate High P Benign Intermediate Malignant P
Symptoms
Asymptomatic 2 6 1 0 0.03 6 3 0 0.04
Symptoms 2 12 9 15 13 7 18
Localizations
Gastric 2 13 7 6 17 5 6
Duodenal 0 3 0 0 0 2 1
Jejunal 1 1 0 4 1 1 4
Small bowel 0 1 2 2 0 1 4
Rectal 1 1 0 1 1 1 1
Other localization 0 0 1 1 0 0 2
Maximum diameter
(Mean cm) 2.0 3.5 6.0 15.3 0.01 3.48 4.35 13.33 0.01
Surgical procedures
Elective resection 4 16 9 11 NS 17 9 14 NS
Emercency resection 0 3 1 3 NS 2 1 4 NS
NS: not significant, Statistical analysis: Chi-square test.
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patients, we did not observe significant differences in the
outcome of patients who migrated in another status.T a b l e
3 shows also differences in tumor’s diameter of GISTs, the
surgical procedures and prevalence of symptoms in our
population study group. We observed an higher prevalence
of symptomatic patients in the “high risk/malignant group”
of both the Fletcher’s and Miettines’s classification
(Chi square p 0.03 and p 0.04 respectively).
Follow-up and outcome
Last update of follow up has been conducted on December
2010. Mean follow up was 54 months (median 40.5, range
6-132 months). Five patients were lost to follow-up. Figure
3a shows overall survival (OS) in our population study
group. Seven patients died in the follow-up period (range of
time to death 6-55 months): five patients died for other rea-
sons (colorectal cancer, lung cancer, leukemia, Alzheimer
disease, myocardial stroke), and among these three were
gastric GISTs, one ileal and one rectal; two patients died
because of disease progression (one jejunal, one ileal) but
had yet metastases at the time of surgical resection.
It seems important to highlight that all deaths occur-
ring in the gastric group were related to other diseases,
and none of them were related to the disease progression.
Figure 3b shows the comparison of the overall survival
curves regarding symptoms: patients presenting with an
acute abdomen had a worse outcome comparing with
patients presenting with other symptoms (Long rank
test p 0.047). It is important to highlight, however, that
the two out of three patients who died within this group
were those two ones who died for disease progression
but had yet metastases at the time of the surgical resec-
tion, thus the “acute abdomen” symptom cannot be con-
sidered per se predictive of OS.
Nine patients are still under pharmacological treatment:
five patients with no sign of disease progression (one gas-
tric, two jejunal, one ileal and one rectal GIST), four show-
ing disease progression (two jejunal, one gastric, one
EGIST), one of those requiring a second line therapy.
Discussion
GISTs originate from ICC or from mesenchymal stem
cells throughout the gastrointestinal tract, or in extra-
gastrointestinal structures. EGISTs might present with
different and not specific symptoms and usually have an
aggressive behaviour. GISTs usually affect males and
females with the same rate, however, we reported a mild
prevalence of males, with a M:F rate of 1.61. According
with published literature we reported a peack of inci-
dence at the 6
th decade.
An association between GISTs and other synchronous
tumors, mainly gastrointestinal adenocarcinomas, has
been previously reported [29], even if this association
could be incidental. We reported four GISTs presenting
associated with colorectal cancers (8.5% of our series)
and one patient who presented a synchronous GIST and
lung cancer (2.1% of our series).
Pre-operative histological diagnosis is very uncommon:
Horowitz [30] reported 50% of success rate, higher if
obtained with ultrasound endoscopy; however percuta-
neous biopsy is not recommended due to the high disse-
mination risk.
Clinical presentation is usually related to tumor loca-
tion, biological features, and disease spread.
GISTs might be asymptomatic in 4-53% and diagnosis
might be incidental: indeed small tumors may be inciden-
tally detected during radiologic, endoscopic or surgical
procedures. De Matteo reported a mean of symptoms
duration of 6 months before diagnosis [31]. According
with our results, 19.2% of patients had an incidental diag-
nosis of GIST.
Most common symptoms are abdominal, mainly epi-
gastric pain (usually a late symptom due compression of
nearby organs) and gastrointestinal bleeding: this was
reported from 17-53% of the cases, usually due to sub-
mucosal tumors causing compression, ischaemia or infil-
tration of the up-leading mucosa, and therefore bleeding
[32-40].
The most common symptom in our experience was
abdominal pain (38%), followed by bleeding in the diges-
tive tract (29.8%).
Dysphagia characterized esophageal GIST, tenesmus
rectal GIST. Asthenia is due to anemization. Palpable
abdominal mass is usually reported in larger gastric or
jejunal tumors [32-40]: we reported five patients (10.6%)
with palpable tumors, all with a diameter > 10 cm.
GISTs causing mucosal ulceration and bleeding
usually have a larger diameter, however we also reported
two gastric GISTs with diameter < 3.5 cm, and two duo-
denal GISTs with diameter < 2 cm causing digestive
bleeding. Acute abdominal symptoms are reported in
3-17% of the cases [33-41]. In our experience, there was
a higher prevalence of acute symptoms in the jejunal/
ileal GISTs: indeed five patients out of seven undergone
to an emergency surgical resection (three due to bowel
obstruction and two due GI bleeding), had jejunal/ileal
GISTs.
A higher prevalence of symptomatic patients was seen
in the “high risk/malignant group” of both the Fletcher’s
and Miettinen’s Classifications (Table 3, p < 0.05).
We observed a higher prevalence of high MI in patients
presenting with an acute abdomen comparing with
patients presenting with pain or incidental GISTs, and
moreover patients presenting with acute abdomen
reported a worse survival curve if compared with other
presentation, however, two out three patients who died
in this group had yet metastases at the time of diagnosis.
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tive of survival and outcome, it is however likely that
those ileal GISTs presenting with acute abdomen (e.g.
bowel obstruction) are those tumors with an higher
mitotic rate and thus an higher rate of metastatization
and disease progression. Thus even if the statistical
value of the association is weak, the patients presenting
with “acute abdomen” were those more likely to have
more than one unfavourable prognostic factor.
GIST surgical resections could be differentiated in
“easier resections” or “difficult resections": “easier” are
resections of small GIST (< 2 cm), in easy accessible
a
b
Figure 3 Kaplan-Meier survival curves for GIST patients. a) Overall Survival (OS) of GIST patients,s a m p l es i z e :4 2 .b )O So fG I S Tp a t i e n t s
regarding symptoms at presentation, sample size 41: Acute abdomen 4 patients, Bleeding 14 patients, Pain 14 patients, No symptoms 9 patients
(Logrank test, significance P = 0.0471).
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tion: these criteria matched 19 (40.4%) of our patients;
“difficult” are resections of larger tumors (> 2 cm), in
difficult location as duodenum, rectum, esophageal-gas-
tric junction, or with an higher risk of R1 resection: 28
(59.6%) patients of our series matched these criteria (9
patients required radical demolishing procedures).
Locally advanced GISTs might be candidate to surgical
resection after neo-adjuvant treatment with Imatinib: sur-
gery should be considered after 6 to 12 months of therapy,
o rw h e nt h em a x i m u mo ft h er e s p o n s er a t ei sa c h i e v e d .
Neo-adjuvant therapy might re-define indication to sur-
gery, morbidity and mortality rate after surgical resection.
The role of surgery for residual, relapse or metastatic dis-
ease after Imatinib however, is still under definition [42].
Laparoscopic resection is nowadays a possible choice:
GISTs <50 mm in size can be treated successfully by
laparoscopic surgery if not contraindicated by co-
morbidities [43]. Indeed the National Comprehensive
Cancer Network (NCCN) recently recommended that
“gastric GISTs 5 cm or smaller may be removed through
laparoscopic wedge resection” w h e nt h er i s ko fi n t r a o -
perative tumor rupture is low. GISTs larger than 5 cm
m a yb er e s e c t e du s i n gal a p a r o s c o p i co rl a p a r o s c o p i c
assisted technique with hand port, depending on the
tumor location and shape, using protective plastic bag
to minimize the risk of port site recurrence [44,45].
Indeed tumor location might influence surgery quality,
clinical evolution and prognosis.
Conclusion
According with our findings symptoms correlate to
tumor location, to class risk criteria as mitotic index
and risk classifications. However, even due to the small
number of investigated patients and the single centre
experience, we cannot conclude that symptoms are per
se predictive of survival or patient’s outcome.
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